×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Understanding the difference between cure and remission in non-Hodgkin lymphoma and overcoming anxiety and adjusting to life after treatment ends.
Loretta J. Nastoupil, MD, reinforces the role of multidisciplinary care throughout the cancer journey and explains why healthcare professionals such as herself recommend that patients keep an open dialogue with all members of their cancer care team.
Patient Whitney Neighbors discusses the benefits of connecting with MD Anderson’s Integrative Medicine Center and support groups or other integrative medicine clinics following a diagnosis of cancer.
Patient and physician considerations for switching between Rituxan IV and Rituxan Hycela, the subcutaneous formulation, during non-Hodgkin lymphoma treatment.
 
Whitney Neighbors, a patient with diffuse large B-cell lymphoma, shares strategies to help others with non-Hodgkin lymphoma manage the side effects of chemotherapy.
Loretta J. Nastoupil, MD, offers recommendations to help patients with non-Hodgkin lymphoma, such as Whitney Neighbors, overcome their fears about chemotherapy.
Whitney Neighbors, who has diffuse large B-cell lymphoma, and Loretta J. Nastoupil, MD, discuss the difficulties involved in accurately diagnosing non-Hodgkin lymphoma and the importance of a biopsy and proper imaging.
Loretta J. Nastoupil, MD, and her patient Whitney Neighbors recall Neighbors’ initial reactions upon learning of her diagnosis of diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, and recognize that the disease presents with much complexity.
Brielle Urciuoli
The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted 16-0 in support of the agency granting approval to CT-P10, a biosimilar of Rituxan (rituximab), which is a drug used to treat non-Hodgkin lymphoma.
 
Brielle Urciuoli
The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other